Omeros (NASDAQ:OMER) Stock Price Up 10.3% – Here’s What Happened

Omeros Co. (NASDAQ:OMER) shares rose 10.3% on Friday . The stock traded as high as $10.92 and last traded at $10.85. Approximately 474,122 shares changed hands during trading, a decline of 11% from the average daily volume of 533,973 shares. The stock had previously closed at $9.84.

Analysts Set New Price Targets

Several analysts have commented on the stock. RODMAN&RENSHAW raised shares of Omeros to a “strong-buy” rating in a research report on Thursday, November 14th. Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Thursday, December 19th. D. Boral Capital initiated coverage on Omeros in a research report on Monday, December 23rd. They issued a “buy” rating and a $36.00 target price for the company. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Performance

The firm has a market capitalization of $649.62 million, a PE ratio of -4.85 and a beta of 1.97. The business’s 50 day moving average is $8.32 and its two-hundred day moving average is $5.62.

Institutional Trading of Omeros

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its holdings in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after buying an additional 7,016 shares in the last quarter. MML Investors Services LLC lifted its stake in Omeros by 19.2% in the 3rd quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 3,000 shares in the last quarter. SPC Financial Inc. bought a new position in Omeros in the 3rd quarter valued at $77,000. SG Americas Securities LLC purchased a new position in shares of Omeros during the 3rd quarter valued at $80,000. Finally, AQR Capital Management LLC bought a new position in shares of Omeros in the second quarter worth $105,000. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.